Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck Foundation marks World Cancer Day with African First Ladies by providing 194 scholarships of Oncology Training to African doctors from 32 countries. Merck Foundation together with Africa First ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Europe Approves Merck's Cancer Drug For Two Indications On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral hypoxia ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a $105 price target See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze ...

In a heartfelt initiative to raise cancer awareness, the Merck India team has donated inspiring paintings to hospitals across India as part of its ‘Art Against Cancer’ campaign. Aligning with ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.